The French pharmaceutical giant Sanofi announced on Tuesday that it would invest two billion euros within five years in research and development on messenger RNA, to take the turn of this innovative technology at the origin of the first vaccines against Covid-19.
The laboratory announced Tuesday that it would devote 400 million euros per year by 2025 in research on new messenger RNA vaccines, investments which should continue beyond this period.
Known for decades, the principle of messenger RNA could make it possible to create personalized and effective vaccines against cancers, but also treatments against many other diseases.
Health
Coronavirus: Are there only messenger RNA vaccines to get us out of the pandemic?
Health
Coronavirus: "The use of messenger RNA is a revolution, for vaccination as well as for therapies", assures researcher Palma Rocchi
Vaccine
Health
Research
Sanofi